Evolent Health因EBITDA复苏担忧而在KeyBanc下调评级

2026-02-25 23:50

KeyBanc Capital Markets downgraded Evolent Health (EVH) to sector weight from overweight citing concerns over the company's EBITDA moving forward.
The bank does not have a price target.
KeyBanc's note came out Tuesday, the same day the company reported Q4 financial results that beat on both lines.
However, analyst Matthew Gillmor said that EBITDA this year will be heavily weighted in H2 at 70%. He added that "we expect Street EBITDA for 2027 ($187M) will move lower."
Evolent's "late-stage pipeline remains strong, and renewal rates with existing customers is high," Gillmore noted. "This reflects strong demand among health plans to control specialty costs (esp. oncology) and is supporting EVH's ability to shift its at-risk contracts to the PS 2.0 model, which has better downside protection."

More on Evolent Health